# OnCo record nct04082364 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04082364/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04082364", "NCT04082364" ;
  schema:name "Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer"@en ;
  schema:description "A phase 2/3 trial of Margetuximab, Retifanlimab and Trastuzumab in HER2-positive gastric cancer, run by MacroGenics, completed."@en ;
  schema:url <https://onco.cc/trials/nct04082364/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04082364> ;
  onco:status "completed" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2/3" ;
  onco:cancers <https://onco.cc/cancers/gastric-her2-positive/> ;
  onco:drugs <https://onco.cc/drugs/margetuximab/>, <https://onco.cc/drugs/retifanlimab/>, <https://onco.cc/drugs/trastuzumab/> ;
  onco:companies <https://onco.cc/companies/macrogenics/> .